<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846182</url>
  </required_header>
  <id_info>
    <org_study_id>SPLD-016-12F</org_study_id>
    <secondary_id>6125</secondary_id>
    <nct_id>NCT01846182</nct_id>
  </id_info>
  <brief_title>Research Examining Gulf War Illness in Our Nations Service Members</brief_title>
  <acronym>REGIONS</acronym>
  <official_title>RCT of Duloxetine &amp; Pregabalin for the Treatment of Gulf War Illness in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from&#xD;
      Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive.&#xD;
      GWI refers to a complex of symptoms that typically include widespread chronic pain,&#xD;
      persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep&#xD;
      disturbances and unexplained fatigue. These symptoms are similar to that of fibromyalgia&#xD;
      syndrome (FMS), another multi-symptom condition. Whereas, effective treatments for GWI have&#xD;
      yet to be found, the FDA has approved duloxetine and pregabalin for the treatment of FMS. The&#xD;
      lack of progress in finding effective treatments for GWI, and the similarities between GWI&#xD;
      and FMS, provides a rationale for determining if these medications can provide relief to&#xD;
      Veterans who suffer from GWI. This randomized controlled trial will test the efficacy of&#xD;
      Duloxetine and Pregabalin for treating Gulf War Veterans who suffer from GWI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from&#xD;
      Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive.&#xD;
      GWI refers to a complex of symptoms that typically include widespread chronic pain,&#xD;
      persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep&#xD;
      disturbances and unexplained fatigue. This symptom profile is similar to that of fibromyalgia&#xD;
      syndrome (FMS), a multi-symptom condition similar to GWI. Whereas, effective treatments for&#xD;
      GWI have yet to be found, progress has been made in identifying medications to treat FMS. For&#xD;
      example, the FDA has approved a number of medications including Duloxetine and Pregabalin for&#xD;
      the treatment of FMS. Compared to placebo (PBO) Duloxetine (a serotonin norepinephrine&#xD;
      reuptake inhibitor) and Pregabalin (an alpha-2-alpha-subunit calcium-channel ligand)&#xD;
      significantly improved pain responses and fatigue. The capacity of Duloxetine to increase&#xD;
      central levels of serotonin and norepinephrine as well as the more complex alterations of&#xD;
      neurotransmitters and central nervous system (CNS) mediators of pain attributed to pregabalin&#xD;
      are thought to be responsible for the medication's effects on pain, mood and sleep. Clinical&#xD;
      practice and one open-label trial support the use of these medications in combination to&#xD;
      achieve optimal symptom improvement amongst GWI sufferers; however, such combinations have&#xD;
      not been formally tested in randomized controlled trials. The lack of progress in finding&#xD;
      effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale&#xD;
      for determining if these FDA approved medications can provide significant symptomatic relief&#xD;
      to Veterans who suffer from GWI. Central Texas is home to one of the highest number of Gulf&#xD;
      War Veterans in the nation, thus the investigators' research team is ideally situated to&#xD;
      conduct the proposed study. In a randomized, double-blind, controlled trial, 180 Veterans who&#xD;
      meet defining criteria for GWI and whose symptom profile includes chronic widespread pain and&#xD;
      sleep disturbances will be treated with one of the following medications; 1) AM Duloxetine+&#xD;
      PM placebo (PBO); 2) PM Pregabalin + AM PBO or 3) AM PBO + PM PBO. All active treatments will&#xD;
      titrate from a lower dose in 2-week increments to the full therapeutic doses (FDA-approved&#xD;
      for FMS). The outcome of the PBO double-dummy period will be compared statistically with 18&#xD;
      weeks of active therapy (weeks 5-22).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated by Funder&#xD;
  </why_stopped>
  <start_date type="Actual">June 24, 2015</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three arms comparing placebo to duloxetine and pregabalin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain by Likert Scale</measure>
    <time_frame>120 days</time_frame>
    <description>Likert scale of pain rating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>Assessed every 2 weeks</time_frame>
    <description>Side effects checklist</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Multiple and Unreliable</measure>
    <time_frame>Assessed every 2 weeks up to 34 weeks</time_frame>
    <description>Reliability of measurement is highly suspect and data are not suitable for analysis.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Gulf War Illness</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg of duloxetine in the AM for 20 weeks and placebo in PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg of pregabalin in the PM for 20 weeks and placebo in AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo in the AM &amp; PM for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>serotonin norepinephrine reuptake inhibitor</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>alpha-2-alpha subunit calcium channel ligand</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Living in Central Texas near Killeen, Austin, Temple or Waco&#xD;
&#xD;
          -  Served on active military duty and deployed to the Persian Gulf region for some period&#xD;
             between August 1990 &amp; July 1991&#xD;
&#xD;
          -  English speaking and able to understand the consent form and study questionnaires&#xD;
&#xD;
          -  Willing to be randomized to treatment and participate in 1-month follow up&#xD;
&#xD;
          -  men &amp; women between the ages of 43 to 70&#xD;
&#xD;
          -  meet Kansas GWI case definition for the diagnosis of GWI&#xD;
&#xD;
          -  report a baseline score &gt; 4 on a 10-point Pain Visual Analog Scale (VAS)&#xD;
&#xD;
          -  female participants of childbearing potential must test negative for pregnancy at the&#xD;
             time of enrollment based on a urine pregnancy test and agree to use a reliable method&#xD;
             of birth control (for example, oral contraceptives or Norplant; a reliable barrier&#xD;
             method of birth control [diaphragms with contraceptive jelly; cervical caps with&#xD;
             contraceptive jelly; condoms with contraceptive foam); intrauterine devices; partner&#xD;
             with vasectomy; or abstinence) during the study and for 2 months following the last&#xD;
             dose of the study drug. [Note that this inclusion criterion applies only to females of&#xD;
             childbearing potential. Females of childbearing potential are defined as women not&#xD;
             surgically sterilized and between menarche and 2 years post-menopause.]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable or poorly controlled chronic medical illness such as Diabetes type-II,&#xD;
             Hypertension (HTN), heart disease, endocrine disorders, narrow angle glaucoma&#xD;
&#xD;
          -  Significant Central Nervous System disease including transient ischemic attacks (TIAs)&#xD;
             or stroke, Dementia, syncopal episodes, severe head trauma, multiple sclerosis&#xD;
&#xD;
          -  Serious or advanced heart disease or clinically relevant abnormal electrocardiogram&#xD;
             (ECG), postural hypotension&#xD;
&#xD;
          -  Untreated sleep apnea or body mass index placing patients at risk for undiagnosed&#xD;
             sleep apnea (BMI&gt; 35 kg/m2)&#xD;
&#xD;
          -  Diabetes type-I and patients with Diabetes type-II associated with peripheral&#xD;
             neuropathy, hepatitis, liver failure/cirrhosis&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  History of hypersensitivity reaction to pregabalin, duloxetine, venlafaxine; active&#xD;
             treatment with duloxetine or pregabalin; History of failure of duloxetine or&#xD;
             pregabalin at therapeutic doses; history of angioedema reaction to pregabalin&#xD;
&#xD;
          -  Active systemic infectious disease such as tuberculosis and HIV, shingles&#xD;
&#xD;
          -  Autoimmune mediated illnesses such as systemic lupus erythematosis, rheumatoid&#xD;
             arthritis, scleroderma&#xD;
&#xD;
          -  History of mental illness requiring hospitalization (depression, bipolar illness, post&#xD;
             traumatic stress disorder, history of suicide attempts, psychosis, schizophrenia&#xD;
             spectrum); Current major depression of dysthymia; patients lacking capacity to make&#xD;
             medical decisions&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of evaluation; Active&#xD;
             ongoing use of the following agents: desvenlafaxine, fenfluramine, linezolid,&#xD;
             milnacipran, phentermine, tryptophan, tramadol, opiates&#xD;
&#xD;
          -  Current (meets criterion within the last 6 months) for drug or alcohol dependence&#xD;
             (except for nicotine and caffeine)&#xD;
&#xD;
          -  Cancer other than non-melanoma skin cancers&#xD;
&#xD;
          -  Women who are pregnant or desire to become pregnant, breastfeeding, who use unreliable&#xD;
             contraception methods&#xD;
&#xD;
          -  Those with occupations requiring use and/or operation of hazardous heavy equipment or&#xD;
             professional drivers&#xD;
&#xD;
          -  Patients for whom the potential risk outweighs the potential benefit in the opinion of&#xD;
             the treating psychiatrist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>44 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles J Foulks, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Central Texas Veterans Health Care System, Temple, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System, Temple, TX</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>February 18, 2021</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gulf War Illness</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Gulf War Veterans</keyword>
  <keyword>Cymbalta</keyword>
  <keyword>Lyrica</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT01846182/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment was very difficult.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>60 mg of duloxetine in the AM for 20 weeks&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>300 mg of pregabalin in the PM for 20 weeks&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Unclear due to assignment records.</participants>
                <participants group_id="P2" count="0">Unclear due to assignment records.</participants>
                <participants group_id="P3" count="0">Unclear due to assignment records.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">The data on completion subjects is corrupted and not reliable for interpretation.</participants>
                <participants group_id="P2" count="0">The data on completion subjects is corrupted and not reliable for interpretation.</participants>
                <participants group_id="P3" count="0">The data on completion subjects is corrupted and not reliable for interpretation.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data collection was inaccurate and data are considered unreliable for evaluation.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>60 mg of duloxetine in the AM for 20 weeks&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>300 mg of pregabalin in the PM for 20 weeks&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain</title>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain by Likert Scale</title>
        <description>Likert scale of pain rating</description>
        <time_frame>120 days</time_frame>
        <population>Data collection was inaccurate and data are considered unreliable for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>60 mg of duloxetine in the AM for 20 weeks and placebo in PM&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>300 mg of pregabalin in the PM for 20 weeks and placebo in AM&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pain by Likert Scale</title>
          <description>Likert scale of pain rating</description>
          <population>Data collection was inaccurate and data are considered unreliable for evaluation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>Side effects checklist</description>
        <time_frame>Assessed every 2 weeks</time_frame>
        <population>Data collection was inaccurate and data are considered unreliable for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>60 mg of duloxetine in the AM for 20 weeks&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>300 mg of pregabalin in the PM for 20 weeks&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>Side effects checklist</description>
          <population>Data collection was inaccurate and data are considered unreliable for evaluation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Multiple and Unreliable</title>
        <description>Reliability of measurement is highly suspect and data are not suitable for analysis.</description>
        <time_frame>Assessed every 2 weeks up to 34 weeks</time_frame>
        <population>Data were inaccurately collected and are considered unreliable for interpretation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>60 mg of duloxetine in the AM for 20 weeks&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>300 mg of pregabalin in the PM for 20 weeks&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple and Unreliable</title>
          <description>Reliability of measurement is highly suspect and data are not suitable for analysis.</description>
          <population>Data were inaccurately collected and are considered unreliable for interpretation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire study data are unreliable.</time_frame>
      <desc>Event collection appears to be inadequate and data are considered to be unreliable.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>60 mg of duloxetine in the AM for 20 weeks&#xD;
Duloxetine: serotonin norepinephrine reuptake inhibitor&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>300 mg of pregabalin in the PM for 20 weeks&#xD;
Pregabalin: alpha-2-alpha subunit calcium channel ligand&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>placebo in the AM &amp; PM for 20 weeks&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed by the sponsor. Recruiting was very difficult and there were multiple irregularities in enrollment, data collection, and study management. The data are unreliable for interpretation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles J. Foulks, M.D., ACOS/R</name_or_title>
      <organization>Central Texas Veterans Health Care System</organization>
      <phone>254 743 2643</phone>
      <email>Charles.Foulks@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

